Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib plus FLA chemotherapy in pediatric relapsed or refractory acute leukemia
NL-OMON59844Phase 1Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ziftomenib in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Recommended phase 2 dose determination and Ziftomenib pharmacokinetics. Started Mar 2025; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NL-OMON59844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59844.